A new pharma leader
Media interviews enhanced the company’s profile and credibility
Secured additional private funding
Market cap increased from $12M to $500M+ in just over six months
Stock trading has quadrupled since our engagement
Despite groundbreaking work, AXIM's lack of profile was depressing its stock price. The company was thought of as ‘just another cannabis company’ without full appreciation of the breadth of its pharmaceutical, nutraceutical and alternative energy offer, leading to uncertainty over whether the company had sufficient capital to carry out existing and new clinical trials.
We created a communications plan to deliver the AXIM story to investor and media audiences, positioning the company as a leader in pharma cannabis R&D and products.
Our program included targeted media relations, contributed content and newsjacking, executive profiling through speaking opportunities at investment conferences, and analyst relations. We also advised on the optimum pathway for uplisting, and facilitated dialogue with NYSE/NASDAQ.